DIA's Adaptive Design Scientific Working Group (ADSWG): Best Practices Case Studies for "Less Well-understood" Adaptive Designs. (January 2017)

• Record Type: Journal Article
• Authors: Miller, Eva; Gallo, Paul; He, Weili; Kammerman, Lisa A.; Koury, Kenneth; Maca, Jeff; Jiang, Qi; Walton, Marc K.; Wang, Cunshan; Woo, Katherine; Fuller, Cynthia; Jemiai, Yannis
• Is Part Of: Therapeutic innovation & regulatory science. Volume 51:Number 1(2017:Jan.)
• Page Start: 77
• Page End: 88
• Publication Date: 2017-01
• Subjects: adaptive trials -- phase IIB/III trial designs -- sample size re-estimation -- data monitoring committee -- 2010 FDA Adaptive Design guidance -- adaptive dose selection; Drugs -- Periodicals; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; Drugs -- Testing -- Periodicals; 615.1
• DOI: 10.1177/2168479016665434
• Languages: English
• ISSNs: 2168-4790

Abstract

Adaptive design (AD) clinical trials use accumulating subject data to modify the parameters of the design of an ongoing study, without compromising the validity and integrity of the study. The 2010 US Food and Drug Administration (FDA) Draft Guidance on Adaptive Design Clinical Trials described a subset of 7 primary design types as "less well-understood." FDA defined these designs as those with limited regulatory experience. To better understand the properties of these less well-understood ADs and to promote their use when applicable, the Best Practices Subteam for DIA's Adaptive Design Scientific Working Group conducted an extensive nonsystematic search and reviewed trials from multiple sponsors who had employed these designs. Here, we review 10 specific case studies for which less well-understood ADs were employed and share feedback about their challenges and successes, as well as details about the regulatory interactions from these trials. We learned that these designs and associated statistical methodologies can make difficult research situations more amenable for study and, therefore, are needed in our toolbox. While they can be used to study many diseases, they are particularly valuable for rare diseases, small populations, studies involving terminal illnesses, and vaccine trials, in which it is important to find efficient ways to bring effective treatments to market more rapidly. It is imperative, however, that these methodologies be utilized appropriately, which requires careful planning and precise operational execution.